Positive effect of erythrocyte-delivered dexamethasone in ataxia-telangiectasia

ABSTRACT

Objective: Ataxia-telangiectasia (AT) is a rare, devastating neurodegenerative disease presenting with early-onset ataxia, oculocutaneous telangiectasia, immunodeficiency, radiosensitivity, and proneness to cancer. In a previous phase 2 study, we showed that 6 monthly infusions of autologous erythrocytes loaded with dexamethasone (EryDex; EryDel, Urbino, Italy) were effective in improving neurologic impairment in young patients with AT. The present article reports the results of the extension of this study for an additional 24-month period.

Methods: After the end of the first trial, 4 patients continued to be treated with monthly EryDex infusions for an additional 24 months, and their clinical outcome was compared with that of 7 age-matched patients who stopped the treatment after the first 6 infusions. The protocol included serial assessment of ataxia (by International Cooperative Ataxia Rating Scale) and adaptive behavior (by Vineland Adaptive Behavior Scales) and clinical and laboratory tests revealing treatment- and steroid-dependent adverse effects, if present.

Results: Patients in the extended study experienced a continuous neurologic improvement with respect to their pretreatment status, whereas controls showed a progressive neurologic deterioration (according to the natural history of the disease) after the discontinuation of the treatment. The delivery system we adopted proved to be safe and well-tolerated, and none of the side effects usually associated with the chronic administration of corticosteroids were observed during the entire trial.

Conclusions: These promising preliminary results call for a large-scale controlled study on protracted treatment of patients with AT with dexamethasone-loaded erythrocytes.

Neurol Neuroimmunol Neuroinflamm 2015;2:e98; doi: 10.1212/NXI.0000000000000098

GLOSSARY

AT = ataxia-telangiectasia; ATM = ataxia telangiectasia mutated; DSP = dexamethasone phosphate; ICARS = International Cooperative Ataxia Rating Scale; VABS = Vineland Adaptive Behavior Scales.

Ataxia-telangiectasia (AT) is a rare genetic disease caused by mutations in the ataxia telangiectasia mutated (ATM) gene, which results in a multisystemic disorder presenting with early-onset ataxia, oculocutaneous telangiectasias, progressive supranuclear ophthalmoplegia, immunodeficiency, recurrent sinopulmonary infections, radiosensitivity, and proneness to cancer. In the classic form, patients are wheelchair-dependent by the age of 10 years, and their life expectancy is approximately 25 years. No effective disease-modifying therapy is presently available.

Observational studies have suggested that betamethasone may be effective in improving neurologic functions in patients with AT. A controlled short-term trial confirmed the efficacy of...
### Table: Demographic data, diagnostic characteristics, and response to treatment

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Sex</th>
<th>Age, y/mo</th>
<th>ATM genotype</th>
<th>ATM protein</th>
<th>ICARS Δ score 0-7*</th>
<th>ICARS Δ score 7-30*</th>
<th>ICARS Δ score 0-30*</th>
<th>ICARS Δ score 7-30*</th>
<th>VABS Δ aa 0-7*</th>
<th>VABS Δ aa 0-30*</th>
<th>VABS Δ aa 7-30*</th>
<th>DSP mean dose 1-6a</th>
<th>DSP mean dose 7-30a</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Continuers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>02-01</td>
<td>M</td>
<td>8/8</td>
<td>6679C&gt;T/8484del A</td>
<td>10%</td>
<td>-4</td>
<td>-11</td>
<td>0/8</td>
<td>1/5</td>
<td>0/9</td>
<td>4.1</td>
<td>8.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>02-02</td>
<td>M</td>
<td>8/7</td>
<td>5979del5/7408T&gt;G</td>
<td>20%</td>
<td>3</td>
<td>-5</td>
<td>0/4</td>
<td>0/9</td>
<td>0/5</td>
<td>2.4</td>
<td>9.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>02-05</td>
<td>M</td>
<td>14/2</td>
<td>4512+1 G&gt;T/3576 G&gt;A</td>
<td>ND</td>
<td>-2</td>
<td>-15</td>
<td>1/2</td>
<td>6/1</td>
<td>4/9</td>
<td>17.5</td>
<td>10.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>02-08</td>
<td>M</td>
<td>10/2</td>
<td>6679C&gt;T/6679C&gt;T</td>
<td>Absent</td>
<td>-7</td>
<td>-9</td>
<td>-2</td>
<td>3/5</td>
<td>2/5</td>
<td>4.2</td>
<td>10.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Discontinuers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>01-01</td>
<td>F</td>
<td>11/7</td>
<td>ND</td>
<td>Absent</td>
<td>-12</td>
<td>6</td>
<td>18</td>
<td>2/9</td>
<td>1</td>
<td>-1/9</td>
<td>9.6</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>01-02</td>
<td>F</td>
<td>8/2</td>
<td>ND</td>
<td>Absent</td>
<td>-16</td>
<td>5</td>
<td>23</td>
<td>2/10</td>
<td>1/10</td>
<td>-1</td>
<td>8.5</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>01-04</td>
<td>M</td>
<td>10/8</td>
<td>7517del4?</td>
<td>Absent</td>
<td>-11</td>
<td>7</td>
<td>18</td>
<td>2/3</td>
<td>0/8</td>
<td>-1/7</td>
<td>18.6</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>01-05</td>
<td>M</td>
<td>10/1</td>
<td>7197delC/T/7197delT</td>
<td>Absent</td>
<td>-7</td>
<td>-3</td>
<td>-4</td>
<td>3</td>
<td>1/5</td>
<td>-1/7</td>
<td>3.5</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>01-07</td>
<td>F</td>
<td>19/2</td>
<td>3496C&gt;T/9139C&gt;T</td>
<td>Absent</td>
<td>-12</td>
<td>14</td>
<td>26</td>
<td>1/3</td>
<td>0/1</td>
<td>-1/2</td>
<td>17.4</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>01-11</td>
<td>F</td>
<td>13/2</td>
<td>3802del4?</td>
<td>Absent</td>
<td>-17</td>
<td>2</td>
<td>19</td>
<td>1/6</td>
<td>1/2</td>
<td>-0/4</td>
<td>14.5</td>
<td>ND</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ATM = ataxia telangiectasia mutated; DSP = dexamethasone phosphate; ICARS = International Cooperative Ataxia Rating Scale; ND = not done; VABS = Vineland Adaptive Behavior Scales.

*Variations of total ICARS score/VABS average age (aa; expressed in y/mo) in subsequent assessments. 0: baseline assessment; 7: assessment performed after the 6th infusion; 30: assessment performed after the 30th infusion in continuers (4 patients) and 24 months after the interruption of the treatment in discontinuers (7 patients). Ataxia improvement is expressed by a reduction of ICARS score.

**Table continued...**

**METHODS** At the end of the first 6-month trial, 4 male patients (mean age 11.6 years; SD 2.8 years; range 8.7–14.2 years) stopped the treatment after the sixth infusion, and were switched to continue EryDex treatment. So far they have been treated monthly for an additional 24-month period.

The extension was authorized by the Ethic Committee. Standard protocol approvals, registrations, and patient consents. The extension was authorized by the Ethic Committee. Current Controlled Trial registration 2010-022315-52. Standard protocol approvals, registrations, and patient consents. The extension was authorized by the Ethic Committee. Current Controlled Trial registration 2010-022315-52.

**RESULTS** After 6 infusions, patients experienced a clinical improvement of about 5 points on the International Cooperative Ataxia Rating Scale (ICARS) without the occurrence of steroid-dependent adverse events. The improvement was more relevant in patients presenting with less neurologic impairment of the DSP loading procedure into the bloodstream for about 20–30 days. After 6 infusions, patients experienced a significant improvement in adaptive behavior, assessed by Vineland Adaptive Behavior Scales (VABS), without the occurrence of steroid-dependent adverse events. The improvement was more relevant in patients presenting with less neurologic impairment of the DSP loading procedure into the bloodstream for about 20–30 days.

**CONCLUSION** The results of the extension of the preliminary study for an additional 24-month period.
RESULTS The table summarizes the clinical response to the treatment at the end of the first 6 months (11 patients) and after 24 further months in continuers (4 male patients) and discontinuers (7 patients; 2 male, 5 female). The mean DSP incorporation during both the original and extended trials is also shown. At the end of the first 6-month trial, ICARS and VABS scores of continuers and discontinuers were ICARS 52.2 ± 7.1 vs 43 ± 2.9 and VABS 6 ± 2.3 vs 8.2 ± 0.6, respectively.

After 30 months, the patients in the extended study experienced an improvement in ICARS score of 10.7 points (SD 6.75; range 2–17) with respect to the score obtained at basal clinical evaluation. Conversely, the ICARS score of the 7 patients who discontinued the treatment worsened by 6.7 points (SD 6.5; range +3–16) (Mann-Whitney U = 1.00; z = 2.45; p = 0.013803). Moreover, all continuers and only 1 of 7 discontinuers improved their ICARS score (Fisher exact test, p = 0.0152). Correspondingly, VABS average age improved by 2.10 years (SD 2.4 years; range 9 months–6.1 years) and by 0.9 years (SD 1 year; range −1.6 to +1.10 years) in continuers and discontinuers, respectively (Mann-Whitney U = 5.50; z = 1.60; p = 0.10). Moreover, ICARS scores at the end of the first 6-month trial and after 30 months improved by 8.2 points (SD 5.8; range 2–17) in the continuers and worsened by 17.8 points (SD 6.9, range −4–26) in the discontinuers (Mann-Whitney U = 0.00; z = 2.64; p = 0.008). Ataxia improved in 4 of 4 continuers and in 1 of 7 discontinuers (Fisher exact test, p = 0.015) (figure). Concomitant variations in VABS among continuers and discontinuers were 2.6 years (SD 2.3 years; range 0.5–4.9 years) and −1.7 years (SD 11 months; range −4 months +2.9 years), respectively (Mann-Whitney U = 0.00; z = 2.64; p = 0.008).

No steroid-dependent adverse reactions were observed during the entire treatment period. Standard laboratory tests, physical examination, vital signs, and ECG were all normal. Additional laboratory parameters such as cholesterol (total, high-density lipoprotein, and low-density lipoprotein), glycosylated hemoglobin (HbA1c), and blood and urinary cortisol were all within the normal range. CD4⁺ lymphocyte count remained stable during the treatment period but below the normal range for 3 of the 4 patients. Blood α-fetoprotein levels increased in all patients, regardless of the treatment they underwent.

DISCUSSION Long-term corticosteroid administration is effective in slowing the progression of Duchenne muscular dystrophy. We recently reported a statistically significant improvement in ataxic symptoms with DSP-loaded red cells in a cohort of young patients with AT. Although this new treatment did not have the usual side effects of chronic steroid treatment, it was apparently less effective than oral betamethasone treatment, which resulted in a symptomatic effect of the treatment rather than a plastic change involving the basic pathogenetic conditions once steroids were interrupted would suggest a symptomatic effect of the treatment rather than a plastic change involving the basic pathogenetic
mechanism of the disease. Otherwise, the persistent clinical improvement we observed so far in the continues conflicts with this hypothesis.

Several methodologic limitations (lack of blinding and placebo in the treatment assignment, small size of the sample, lack of external clinical criteria for patient enrollment) affect our study, which was based on an empiric post hoc observation. The lack of AT-dedicated rating scales is a further intrinsic methodologic limitation. Nevertheless, in the face of such a dramatic, untreatable disease, any clinical observation suggesting a potential treatment deserves to be considered.

Whatever the biological effect of steroids in AT, present data support the view that a protracted treatment may delay and perhaps bias the natural course of the disease. Moreover, the delivery system we adopted was confirmed to be safe and well-tolerated, since after this extended period of time no side effects could be detected. A large-scale controlled study on protracted steroid treatment by DSP loaded into erythrocytes in patients with AT is mandatory in order to verify these preliminary data.

**AUTHOR CONTRIBUTIONS**

All authors have made a substantial contribution to qualify for authorship. Each author listed on the manuscript has seen and approved the submission of this version of the manuscript and takes full responsibility for the manuscript. Vincenzo Leuzzi: drafting/revising the manuscript, analysis and interpretation of clinical and biochemical data, acquisition of data. Roberto Micheli: drafting/revising the manuscript, analysis and interpretation of clinical and biochemical data, acquisition of data. Daniela D’Agnano: drafting/revising the manuscript, analysis and interpretation of clinical and biochemical data, acquisition of data. Anna Molinaro: drafting/revising the manuscript, analysis and interpretation of clinical and biochemical data, acquisition of data. Maria C. Pietrogrande: drafting/revising the manuscript, analysis and interpretation of clinical and biochemical data, acquisition of data. Pierino Ferremi Leali: drafting/revising the manuscript, analysis and interpretation of clinical and biochemical data, acquisition of data. Isabella Quinti: drafting/revising the manuscript, analysis and interpretation of clinical and biochemical data, acquisition of data. Mirella Molinaro: drafting/revising the manuscript, analysis and interpretation of clinical and biochemical data, acquisition of data. Vincenzo Leuzzi: drafting/revising the manuscript, analysis and interpretation of clinical and biochemical data, acquisition of data.

**ACKNOWLEDGMENT**

The authors thank Drs. L. Buccone, C. Pignata, F. Specchia, and A. Trizzino for referring patients; the associations (Amici di Valentina, Noi per Lorenzo, AISAv, Alif) that assisted the families in traveling and staying in Rome or Brescia; all the hospital personnel (doctors, nurses, physiotherapists, technicians, etc.); and the sponsor EryDel for providing economic support and the EryDex system.

**STUDY FUNDING**

EryDel provided economic support and the EryDex System.

**DISCLOSURE**

V. Leuzzi, R. Micheli, D. D’Agnano, A. Molinaro, T. Venuti, A. Plebani, A. Soresina, M. Marin, and P. F. Leali report no disclosures. I. Quinti is on the scientific advisory board for CSL Behring, is on the editorial board for Frontiers in Immunology, and received research support from Jeffrey Modell Foundation. M.C. Pietrogrande reports no disclosures. A. Finochietti received research support from Italian Ministry of Health. E. Fazzi and L. Chessa report no disclosures. M. Magnani is the CSO of EryDel SpA, holds a patent for encapsulation of agents within erythrocytes, received research support from Fondazione Cassa di Risparmio di Fano, and holds stock in EryDel SpA. Go to Neurology.org/an for full disclosure forms.

**REFERENCES**


Positive effect of erythrocyte-delivered dexamethasone in ataxia-telangiectasia
Vincenzo Leuzzi, Roberto Micheli, Daniela D'Agnano, et al.

*Neurol Neuroimmunol Neuroinflamm* 2015;2;
DOI 10.1212/NXI.0000000000000098

This information is current as of April 9, 2015